Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Nasopharyngeal Carcinoma 2 Lymphoma, Large B-Cell, Diffuse 2 Carcinoma, Hepatocellular 2 Advanced Solid Tumor 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pheochromocytoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Paraganglioma, Extra-Adrenal 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma Metastatic 1 Osteosarcoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Lymphoma 1 Lung Neoplasms 1 Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1 Gynecological Cancer 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Esophageal Squamous Cell Carcinoma 1 Digestive System Diseases 1

Interventions

anlotinib 2 penpulimab 1 Laparoscopy 1 Injections, Spinal 1 Injections, Epidural 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Gynecological Cancer × penpulimab × Clear all

NCT05028504 2023-12-27

ALTER-GO-020

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡